Autolus Therapeutics is set to reduce its headcount by around 20% and seek a partner for one of its dual-targeted CAR-T candidates. The changes will increase Autolus’ focus on CD19 CAR-T cell therapy AUTO1 ahead of the anticipated delivery of pivotal data on the candidate next year. Source: Fierce Biotech 6/1/2021